GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Total Inventories

Xbrane Biopharma AB (STU:7XB) Total Inventories : €16.55 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Total Inventories?

Xbrane Biopharma AB's total inventories for the quarter that ended in Mar. 2024 was €16.55 Mil. Xbrane Biopharma AB's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was €13.05 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Xbrane Biopharma AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €-0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Xbrane Biopharma AB's Days Inventory for the three months ended in Mar. 2024 was 2,815.38.

Inventory Turnover measures how fast the company turns over its inventory within a year. Xbrane Biopharma AB's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.03.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Xbrane Biopharma AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 10.47.


Xbrane Biopharma AB Total Inventories Historical Data

The historical data trend for Xbrane Biopharma AB's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Total Inventories Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.57 9.55

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.79 8.16 11.30 9.55 16.55

Xbrane Biopharma AB Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Xbrane Biopharma AB  (STU:7XB) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Xbrane Biopharma AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(23.837+0.75 * 0.102+0.5 * 16.549-44.583
-0-0)/1529.48
=-0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Xbrane Biopharma AB's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=13.051/0.423*365 / 4
=2,815.38

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Xbrane Biopharma AB's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0.423 / 13.051
=0.03

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xbrane Biopharma AB's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=13.051 / 1.246
=10.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Xbrane Biopharma AB Total Inventories Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines